Clinical Trial Update: A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 pilot study evaluated the safety and immunologic activity of AGS-004, an autologous HIV immunotherapeutic agent, in HIV-infected individuals. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Human Immunodeficiency Virus Infection

Drugs mentioned

• AGS-004

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: HIV Seropositivity, Acquired Immunodeficiency Syndrome | Phase 1, Phase 2 | Status: COMPLETED